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Abstract
Background: Intestinal Peyer’s patches (PPs) form unique niches for bacteria-immune cell interactions that direct
host immunity and shape the microbiome. Here we investigate how peroral administration of probiotic bacterium
Limosilactobacillus reuteri R2LC affects B lymphocytes and IgA induction in the PPs, as well as the downstream
consequences on intestinal microbiota and susceptibility to inflammation.
Results: The B cells of PPs were separated by size to circumvent activation-dependent cell identification biases due
to dynamic expression of markers, which resulted in two phenotypically, transcriptionally, and spatially distinct
subsets: small IgD+/GL7−/S1PR1+/Bcl6, CCR6-expressing pre-germinal center (GC)-like B cells with innate-like
functions located subepithelially, and large GL7+/S1PR1−/Ki67+/Bcl6, CD69-expressing B cells with strong metabolic
activity found in the GC. Peroral L. reuteri administration expanded both B cell subsets and enhanced the innate-like
properties of pre-GC-like B cells while retaining them in the sub-epithelial compartment by increased sphingosine-
1-phosphate/S1PR1 signaling. Furthermore, L. reuteri promoted GC-like B cell differentiation, which involved
expansion of the GC area and autocrine TGFβ-1 activation. Consequently, PD-1-T follicular helper cell-dependent
IgA induction and production was increased by L. reuteri, which shifted the intestinal microbiome and protected
against dextran-sulfate-sodium induced colitis and dysbiosis.
Conclusions: The Peyer’s patches sense, enhance and transmit probiotic signals by increasing the numbers and
effector functions of distinct B cell subsets, resulting in increased IgA production, altered intestinal microbiota, and
protection against inflammation.
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Background
Interactions between the gut microbiota and the im-
mune system are important for host physiology and sus-
ceptibility to disease, but also for the therapeutic
responses to cancer immunotherapies [1–3]. Accumulat-
ing evidence reveals that specific bacterial taxa can
regulate the differentiation and function of intestinal im-
mune cells [2, 4]. Limosilactobacillus reuteri (previously
named Lactobacillus reuteri) [5] is such a host-specific
symbiont that is highly diversified and adapted to the
mammalian and avian gastrointestinal (GI) tract [6].
Multiple beneficial effects of L. reuteri have been dem-
onstrated both in clinical and preclinical studies, includ-
ing prevention and/or amelioration of inflammatory
diseases and GI tract disorders [7]. Using the dextran
sulfate sodium (DSS)-colitis model, we have previously
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demonstrated that L. reuteri R2LC treatment strengthens
the intestinal mucosal barrier and represses inflammation
[8]. These observations justify attempts to use probiotic
bacteria for manipulating the host immune system to main-
tain intestinal homeostasis and combat inflammation, as
well as to enhance the efficacies of tumor-targeting treat-
ments [3]. In addition to influencing the host, the intestinal
microbiota is shaped by the host through a multi-layer sys-
tem that involves epithelium, antibacterial molecules, innate
and adaptive immune cells, as well as immunoglobulin A
(IgA) antibodies secreted by plasma cells interspersed
throughout the mucosa [9, 10]. Absence or impaired selec-
tion of IgA causes gut microbiota dysbiosis and leads to
systemic immune effects and overt inflammation [11].
Induction of IgA primarily takes place in the germinal
centers (GCs) of the intestinal lymphoid tissue, the
Peyer’s patches (PPs) [12]. The PPs are in direct contact
with luminal antigens that are captured at the follicle-
associated-epithelium (FAE) for subsequent transport to
the sub-epithelial dome (SED) occupied by antigen-
presenting dendritic cells (DCs) and numerous B lym-
phocytes [12–14]. Activated IgD+ pre-GC B cells in the
SED are reported to express CCR6 and interact with
DCs to obtain signals for IgA induction [12, 15]. The
DCs serve as an important source of transforming
growth factor β (TGFβ), the key factor that drives IgA
class switch recombination [16, 17] and supports the B
cell IgA-switch in the SED [13]. However, the dominant
part of IgA induction occurs in the GC regions of the
PPs [10], where the GC reactions constantly occur due
to the continuous exposure of PPs to gut microbiota [12,
14]. Here, proliferating Ki67+, GL7+ GC B cells express
activation-induced cytidine deaminase (AICDA) and
BCL6, which are critical factors for antibody clonal ex-
pansion and affinity maturation [10, 12]. Despite recent
progress within the field, a detailed understanding of the
interactions between intestinal microbiota and the im-
mune cells of PPs is still lacking.
Here we explore how the probiotic bacterium L. reu-
teri R2LC affects the B cells of PPs and consecutive in-
testinal IgA induction and production, as well as the
downstream consequences on intestinal microbiota and
susceptibility to inflammation. To limit possible biases
of cell identification by their dynamic expression of sur-
face markers, the CD19+B220+ PPs B lymphocytes were
sorted by size. This resulted in two phenotypically dis-
tinct subsets that were transcriptionally and spatially
separated: large GC-like B cells of the GC area, and
smaller pre-GC B cells with an innate-like phenotype
residing sub-epithelially. Following peroral administra-
tion of L. reuteri R2LC for seven days, both population
sizes expanded and their respective intrinsic functions
were strengthened. Ultimately, L. reuteri R2LC treatment
modified the intestinal microbiota through enhanced
IgA induction and production, as well as reduced in-
flammation and microbiota dysbiosis in a model of in-
flammatory bowel diseases (IBD).
Results
Phenotypic and transcriptional distinction between B cells
in Peyer’s patches
The B cells of the PPs in wild-type mice were character-
ized on cell size using unbiased regular and imaging flow
cytometry to account for potential dynamics in the ex-
pression of surface markers. We found that the
CD3-CD19+B220+ B cells clustered into two subsets ac-
cording to their size (Fig. 1a, b, Additional file 1: Fig.
S1A, B), where 38.7% were large B cells (120–210 μm2)
of higher granularity than small B cells (61.3%, 60–
120 μm2), while size-separated clusters were not ob-
served for the B cells from spleen or mesenteric lymph
nodes (MLNs) in healthy mice. Within the PPs, immu-
nohistochemical staining demonstrated that the two B
cell subsets occupied distinct niches (Fig. 1c), where the
large B cells were observed at the GL7+/Ki67+/IgA+ re-
gion, corresponding to the GC area [10, 15], while the
small-sized B cells were predominantly found in the
sub-epithelial compartment (Fig. 1c, d). Intravital micro-
copy confirmed that small B lymphocytes were abundant
in the SED pre-GC niche [12, 14], where they were also
detected interspersed between the FAE (Additional file
1: Fig. S1C, D, Additional file 2: movie S1, Additional file
3: movie S2), directly facing the luminal antigens.
Transcriptional profiling of the size-sorted PPs
CD19+B220+ B cells (Additional file 1: Fig. S2A-G) re-
vealed that both subsets expressed B cell lineage-specific
transcripts (Additional file 1: Fig. S2B) and Ig genes in
similar patterns but at different levels (Additional file 1:
Fig. S2C), indicating a difference in affinity maturation
[18]. Clustering analysis showed distinct subgroups of
the large and small B cells (Additional file 1: Fig. S2D),
where approximately 2290 genes were significantly dif-
ferentially expressed (FDR q < 0.05). Gene ontology en-
richment analysis (Biological Process) demonstrated that
large B cells contain significantly more transcripts en-
coding proteins associated with cell cycle and prolifera-
tion, or engaged in metabolic processes including
oxidation-reduction, transport, lipid oxidation, and tri-
carboxylic acid cycle (Fig. 1e, upper panel, Additional file
1: Table S1), especially linked with the glycolysis- and
hypoxia-pathways (Additional file 1: Fig. S2F). These
transcriptional programs support a high degree of bio-
synthesis and growth of PPs large B cells, similar to ob-
servations of the newly formed GC B cells of spleen and
lymph nodes expressing the metabolic checkpoint regu-
lators Gsk-3α (glycogen synthase kinase 3) and Hif-1α
[19, 20]. Indeed, the large B cells expressed higher levels
of Mki67, Gsk-3α, and Hif-1α compared to the small B
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cells (Additional file 1: Fig. S2G). Hypoxic signals were
identified within the GL7+CD35+ areas using the hyp-
oxia probe pimonidazole (Additional file 1: Fig. S2H). In
addition, heat maps of mRNA expression analyzed by
qRT-PCR revealed that large B cells expressed signifi-
cantly higher levels of genes critical for B cell cognition
and T cell interaction (BAFFR, CD40, CD274, ICOSL,
and TACI) [21], and differentiation (AICDA and TGFβ1),
Myd88, and Integrin α4 and β7 compared to small B
cells (Fig. 1f).
In contrast, small B cells displayed a gene signature of
innate anti-bacterial immune responses (Fig. 1e–g, Add-
itional file 1: Table S1), involving transcripts encoding
proteins such as defensins (Defa17, Defa3), lysozymes
(Lyz1, Lyz2), and intestinal lactoferrin receptor (Itln1)
(Fig. 1e, lower panel). The anti-bacterial potential of
small B cells was confirmed by immunohistochemistry,
as CD11C-CD19+B220+B cells expressing defensin α3
(DEFa3) were identified in close proximity to the high
DEFa3+ FAE region (Additional file 1: Fig. S2I). Notably,
genes of pattern recognition receptors TLR2, TLR4, the
lipid presenting receptors CD1D, S1PR1, and the chemo-
kine receptor CCR9 were expressed at higher levels in
the small compared to the large B cell subset (Fig. 1g).
In contrast, the expression of nucleic acid sensing TLR7
and TLR9 as well as CD69, the negative regulator of
S1PR1, were expressed at lower levels in small B cells
(Fig. 1g). Both large and small B cells expressed similar
levels of Bcl6 (Additional file 1: Fig. S2G), the master
regulator of GC B cell-fate [22], and genes associated
with B cell migration (Fig. 1g), including CXCR5, CCR6,
and EBI2 [14, 15, 22]. Further, flow cytometry analysis
showed that large B cells more frequently expressed GL7
and at higher levels (Fig. 1h, i), in contrast to the small B
cells that were more often IgD+, CD62L+, CD21+ (CR2),
and exclusively expressed surface S1PR1 (Fig. 1h, i). Ac-
tivated B cells at pre-GC stage have been reported to ex-
press Bcl6 [23], thus implying a potential pre-GC
phenotype of the IgD+/GL7−/S1PR1+/Bcl6, CCR6-ex-
pressing small-B subset.
Taken together, the size of B lymphocytes in PPs is a
good estimator of the B cell activation state and might
therefore allow for separation and studies of specific
populations in response to environmental changes. We
find that large B cells in the PPs are of GC-like pheno-
type, expressing GL7+/S1PR1−/Ki67+/Bcl6 and CD69,
and display intense metabolic activity. In addition, small
B cells represent a heterogeneous group of SED B cells
that exhibit bacterial defense properties, mainly compris-
ing of the pre-GC phenotype [22, 23], but also of IgD+/
CD62L+ naïve B cells [15].
Limosilactobacillus reuteri expands the different
population of Peyer’s patches B cells and enhances their
effector functions
Peroral administration of 108 L. reuteri R2LC for seven
consecutive days specifically expanded the pre-GC-like
and the GC-like B cell subsets, together increasing the
CD3-CD19+B220+ B cell population from 60 to 70% of
total PPs cells (Fig. 2a, Additional file 1: Fig. S3A, B). As
a result, the PPs became substantially enlarged and in-
creased in height (Additional file 1: Fig. S3C), while the
B cell population (CD3-CD19+B220+) in MLNs was not
altered (Additional file 1: Fig. S3D), demonstrating gut-
specific effects. Bacterial strain specificity was tested
using two L. reuteri strains isolated from human breast
milk (ATCC PTA 4659 and ATCC PTA 6475), whereas
R2LC originates from rat intestine. While 4659 ex-
panded only the GC-like B cell population, no difference
was observed between 6475 and the control group (Fig.
2a, Additional file 1: Fig. S3B). We therefore mainly fo-
cused on R2LC, hereafter referred to as “L. reuteri.”
The expansion of the pre-GC-like B cells in L. reuteri-
treated mice was almost exclusively due to increased
number of S1PR1+ B cells (Fig. 2b) with decreased sur-
face expression of S1PR1. These observations imply in-
creased availability of the S1P ligand, as previously
reported [24]. Indeed, L. reuteri-treatment down-
regulated gene expression of S1P lyase (sgpl1) while up-
regulating expression of ceramide synthase (LASS5) in
(See figure on previous page.)
Fig. 1 Phenotypic and transcriptional distinction between B cell subsets in Peyer’s patches. a Flow cytometry of PPs live CD3-CD19+B220+ B
lymphocytes (gated as shown in Fig. S1A) and separated into the small and large B cell subsets by forward scatter area and expressed as mean
FSC-A (size), and the number of small-B and large-B cells per mg tissue (n = 6 mice left panel; n = 24 mice right panel). b Imaging flow
cytometry of the areas (μm2) of small-B and large-B cell from three independent experiments. c, d Immunohistochemistry of PPs stained with
anti-B220 (magenta), anti-CD138 (yellow) and Hoechst (blue) in c or anti-B220 (white), anti-GL7 (green), anti-Ki67 (cyan), anti-IgA (yellow), and
anti-IgD (blue) in d. Scale Bars equal 100 μm or 10 μm in closed-up reviews. e Enrichment of gene ontology categories (Biological Process, BP) for
genes differentially expressed in large B (upper panel) versus small B cells (lower panel) determined by microarray of lin-CD19+B220+ cells sorted
on FSC-A (n = 4 samples per group), the number of genes in each functional category is shown. Data were adjusted by false discovery rate
control (FDR). f, g Displays of heat maps of genes expression by q-RT-PCR in sorted small and large B cells. The expression was normalized to the
mean value of large B and each column represents one sample. h, i Heat maps and histograms depicting expression of surface markers on small
and large B cells (n = 6 mice per group). The frequency of indicated markers (normalized to the mean value of large B cells). i MFI of B cells
positive for GL7 and S1PR1, and percentage in each subset. Data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
using two-tailed Student’s t test
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the PPs (Fig. 2c), suggesting reduced S1P degradation
and amplified S1P synthesis. The involvement of the
S1P/S1PR1 pathway was further assessed using a S1PR1
agonist FTY720 (Fingolimod) [24]. In line with the ob-
servations following L. reuteri-treatment, FTY720-
treatment significantly increased the number of pre-GC-
like, but not to GC-like B cells (Fig. 2d, Additional file 1:
Fig. S3E).
Further, a principal component analysis (PCA) of the
transcriptome data for the size-sorted PPs CD19+B220+
B cells from control and L. reuteri-treated mice revealed
four separated clusters (Fig. 2e). PC1 variation confirmed
the transcriptional distinction between B cells of the
SED and the GC, which separated independently of bac-
terial stimulation. L. reuteri-treatment was found to im-
pact the transcriptional profile of both subsets in two
different ways: one was common for both subsets as they
were shifted towards the right on PC1, whereas the
other was subset-specific, as displacement on PC2 oc-
curred in opposite directions. The differential expression
of genes of large and small B cells in response to L reu-
teri treatment was further analyzed and was found to be
consistent with the PCA analysis (Additional file 1: Fig.
S2D), indicating distinct responses of the B cell subsets
to L. reuteri. Gene ontology enrichment analysis of pre-
GC-like B cells showed that L. reuteri-treatment further
upregulated expression of gene clusters associated with
defense responses to bacteria (Fig. 2f), including Defa3,
Defa21, Lyz1, Fbrs, Pira1, Arhgef1, Mptx2, Itln1, Muc2,
Agr2, Mmp7, and Angptl1. Although no treatment differ-
ence was observed on DEFa3+ protein levels in B cells,
the DEFa3+ B cells co-expressed S1PR1 (Fig. 2g, Add-
itional file 1: Fig. S3F). These data demonstrate that L.
reuteri promotes the bacterial defense gene program of
the S1PR1+ pre-GC-like B cell subset in a S1P/S1PR1-
dependent manner.
L. reuteri increases the numbers of B cells in the PPs GC,
and modifies their functional gene signature
L. reuteri-treatment expanded the GL7+ GC area of the
PPs (Fig. 3a, Additional file 1: Fig. S3G), where more
proliferating Ki67+ B cells were found to accumulate
(Fig. 3c, Additional file 1: Fig. S3H). Flow cytometry con-
firmed that L. reuteri (R2LC and 4659) increased the
number of GL7+ and Ki67+ B cells (Fig. 3b, d). In
addition, active DNA synthesis determined by EdU (5-
ethynyl-2′-deoxyuridine) uptake on the last day of the
experiment occurred in GL7+ but not GL7- B cells (Fig.
3e, left panel), whereas the number of EdU+GL7+B cells
was unaltered (Fig. 3e, right panel). In contrast, tran-
scriptome analysis of the GC-like B cells showed that L.
reuteri-treatment downregulated cell division and cell
cycle gene clusters (Additional file 1: Table S2), and ex-
pression of Mki67, Gsk-3α, and Hif-1α (Fig. 3f). More-
over, the proportion of HIF-1α+ B cells and their HIF-1α
expression were reduced by L. reuteri-treatment (Add-
itional file 1: Fig. S3I). These results indicate that L. reu-
teri stimulate the proliferation and clustering of GC-like
B cells at the GC niche. Furthermore, L. reuteri-treat-
ment upregulated the gene signature of GC function in
these B cells (Fig. 3g), and expressions of TGFβ1 and
TGFβR1. Using flow cytometry, we discovered a signifi-
cant expansion of TGFβ1+ B cells in PPs of L. reuteri-
treated mice (Fig. 3h). The L. reuteri-induction of
TGFβ1 was specific to the TGFβ1-TGFβR1-expressing
GC-like B cell subset, and the tissue concentration of
TGFβ1 did not change (Fig. 3i). In contrast, L. reuteri-
treatment reduced cytokine levels in the PPs including
TNF-α, CXCL1, IL-6, and IL-10 (Fig. 3i), promoting a
non-inflammatory shift of the microenvironment. In
addition, L. reuteri-treatment upregulated the IgA germ-
line transcript (αGT) in PPs (Fig. 3j). These data demon-
strate that L. reuteri enhances the functional gene
expression of GC-like B cells, and promotes their low
proliferative/high T cell-interactive post-GC phenotype
[21] by autocrine stimulation of TGFβ1 signaling [15].
L. reuteri DSM 17938 has previously been reported to
modulate gut microbiome and inhibit autoimmune re-
sponses in immune-compromised Scurfy mice via the
adenosine receptor A2A [25]. To determine whether L.
reuteri R2LC induces PPs B cell responses through ad-
enosine signaling, we generated a mutant strain lacking
the ability to convert AMP into adenosine by impaired
functional 5′-nucleotidase (L. reuteri R2LC_ΔADO).
The effect of the mutant on the PPs B cells subsets did
not differ in any respect from the wild-type R2LC strain
(Fig. 3b, d, h, k). However, the mutant increased the
number of Ki67+ and TGFβ1+ B cells in the PPs
(See figure on previous page.)
Fig. 2 L. reuteri increases the population of Peyer’s patches B cells and enhances their effector functions. a Flow cytometry of small-pre-GC-like
and large-GC-like B cell subsets from control mice or mice treated with 108 cfu L. reuteri (R2LC, 4659 or 6475) perorally for 7 consecutive days (n =
5–12 mice per group). b Numbers of S1PR1+ small pre-GC-like B cells (CD3-CD19+B220+) and their S1PR1 expression (MFI, n = 5–12 mice per
group). c Illustration of enzymes regulating sphingosine-1-phosphate (S1P) homeostasis (top). q-RT-PCR analysis of gene expression (fold change,
n = 6 mice per group) of the S1P pathway (bottom). d Experimental design evaluating the effect of the sphingosine-1-phosphate (S1P) receptor
modulator FTY720 (top), and flow cytometry of B cell subsets (lower panels, n = 10–11 mice per group). e Principal component analysis of the
microarray data, where each dot represents one sample (n = 4 samples per group). f Enrichment of gene ontology categories (BP) for genes
upregulated by L. reuteri in small B cells. g Flow cytometry of DEFa3+ B cells (CD11C-CD19+B220+) in PPs and DEFa3 expression (MFI, n = 5–6
mice per group). Data are presented as mean ± SEM. *p < 0.05, **p < 0.01 using two-tailed Student’s t test
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compared to control mice (Fig. 3d, h). These results in-
dicate that adenosine signaling alone does not determine
the effects by R2LC on PPs B cells.
L. reuteri promotes B cell IgA-responses through the T
follicular helper (Tfh)-PD-1 pathway
As L. reuteri was demonstrated to enhance IgA induc-
tion in PPs, its effects on IgA production and secretion
were investigated. Interestingly, we found that L. reuteri-
treatment increased the density of IgA+ plasma cells in
the lamina propria of both colon and ileum, as well as
increased IgA expression in the ileum (Fig. 4a). Accord-
ingly, higher titers of free IgA were detected in the intes-
tinal lumen, whereas IgA or IgG concentrations in
circulation were not altered (Fig. 4b, c). Following secre-
tion, IgA serves as part of innate immune surveillance
through binding commensal microbiota [26]. Flow cy-
tometry revealed that L. reuteri-treatment enhanced the
proportion of IgA+ bacteria in the ileal flora, as well as
the level of IgA bound per bacteria (IgAhigh) (Fig. 4d,
Additional file 1: Fig. S4A). Increased number of IgAhigh
bacteria was also observed with L. reuteri R2LC_ΔADO
compared to control (Additional file 1: Fig. S4B). L. reu-
teri-treatment did not increase the α-diversity of the
microbiota (Fig. 4e, Additional file 1: Fig. S4C), but in-
duced a shift of bacterial community composition (Fig.
4f, Additional file 1: Fig. S4D). Notably, ileal Clostridia-
ceae, Erysipelotrichaceae and other bacteria belonging to
Firmicutes were less abundant in L. reuteri-treated mice
compared to in control mice (Additional file 1: Fig. S4E).
In contrast, L. reuteri-treatment promoted the expansion
of ileal Bifidobacteriaceae, as well as ileal and colonic
bacterial phylotype S24-7 (affiliated to Bacteroidetes)
(Fig. 4f, Additional file 1: Fig. S4D, E), while the relative
abundance of Lactobacillaceae did not increase at either
site. Together these results demonstrate that administra-
tion of a single species of L. reuteri boosts IgA produc-
tion, thereby shifts the composition of the intestinal
microbiota.
In lymphoid organs, PD-1+CXCR5+ Tfh cells are spe-
cialized in promoting T cell-dependent B cell IgA-
responses [21]. Immunohistochemical staining revealed
that in PPs, the PD-1+ Tfh cells are localized in the GC
area (Fig. 4g). L. reuteri-treatment did not affect the
CD3+TCRαβ+CD4+ T cell population (Additional file 1:
Fig. S4F); however it doubled the number of PD-
1+CXCR5high Tfh cells, which expressed higher levels of
PD-1 (Fig. 4h) and increased the number of IL-21+CD4+
effector T cells and their IL-21 production (Additional
file 1: Fig. S4F). Importantly, the L reuteri-induced ex-
pansion of GC-like B cells was completely dependent on
the Tfh-PD-1 pathway, as demonstrated by either ad-
ministration of PD-1-blocking monoclonal antibodies or
depletion of CD4+ cells (Fig. 4i). PD-1 inhibition also
impaired the ability of L. reuteri-treatment to enhance
IgA production, resulting in reduced levels of IgA-
binding bacteria (Fig. 4j, k). These data demonstrate that
the Tfh-PD-1 pathway is crucial for L. reuteri-induction
of B cell IgA-responses.
L. reuteri provides protection against DSS-induced
intestinal inflammation and disruption of Peyer’s patches
As previously demonstrated [8], DSS induces colitis and
profound inflammation in the colon (Additional file 1:
Fig. S5A, B). Here, we found that it also severely dam-
aged the ileal mucosa (Additional file 1: Fig. S5C) and
reduced the number of CD3-CD19+B220+ B cells in the
PPs by more than 50%. This reduction was due to de-
creased numbers of both pre-GC-like B cells and GC-
like B cells, resulting in reduced PPs size (Fig. 5a, b).
Colitis induced significant B cell accumulation in MLNs
(Additional file 1: Fig. S5D) and caused ileal mucosal in-
filtration of IgA+ plasma cells (Additional file 1: Fig.
S5E), but did not affect the proportion of IgA+ bacteria
in the ileal flora (Additional file 1: Fig. S5F). In contrast,
a significant increase of the level of IgA bound per bac-
teria (IgAlow) was detected in DSS-treated mice when
compared to control (Additional file 1: Fig. S5F).
Prophylactic treatment of L. reuteri for 14 days pre-
vented DSS-induced ileal disruption (Additional file 1:
Fig. S5C), and delayed and attenuated colitis symptoms
(Fig. 5c, Additional file 1: Fig. S5A, B). Disease activity
(See figure on previous page.)
Fig. 3 L. reuteri expands the GC-like B cell population and reprograms its functional gene signature. a, c Immunohistochemistry of the GL7+ area
stained with anti-B220 (magenta), anti-GL7 (green) and anti-Ki67 (cyan). Scale bars equal 100 μm. Representative images of PPs from the control
or L. reuteri-treatment are shown in a and c, and the corresponding quantification shown in Fig. S3G, H. b, d Flow cytometry quantification of
GL7+ B cells (in CD3−CD19+B220+, n = 5–6 mice per group) and Ki67+ cells (n = 5–6 mice per group). e In vivo proliferation assay was performed
by flow cytometry following i.p. injection of EdU. A histogram depicting EdU expression in GL7−, GL7+ or EdU+CD19+B220+B cells and the
number of EdU+GL7+ B cells (n = 6 mice per group). f Expression of Mki67, Gsk-3α, and Hif-1α in large GC-like B cells from control or L. reuteri-
treated mice (GOI, gene of interest; A.U., arbitrary unit). g q-RT-PCR analysis of gene expression levels (n = 6 mice per group) and expression of
TGFβR1 (microarray analysis). h Flow cytometry analyzing the numbers of TGFβ1+ B cells as well as the TGFβ1 levels (MFI, n = 6–18 mice per
group). i The PPs tissue was analyzed for cytokine/chemokine production by Multi-Plex Mesoscale and ELISA, normalized to tissue protein content
(n = 6 mice per group). j Expression of α germline transcripts (αGT) in PPs (n = 6 mice per group). k The numbers of B cells of different subsets in
PPs in untreated mice and in response to L. reuteri R2LC and L. reuteri R2LC_ΔADO (n = 6 mice per group). Data are presented as mean ± SEM.
*p < 0.05, **p < 0.01 using Student’s t test or ANOVA with Tukey’s post hoc test
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index (DAI) [8] revealed that the protective effect was
most obvious for R2LC followed by 4659, but not ob-
served with 6475 (Additional file 1: Fig. S5G). L. reuteri
R2LC_ΔADO-treatment also lowered the DAI compared
to DSS only, demonstrating that the disease-
ameliorating effects by R2LC are not mediated through
adenosine signaling.
L. reuteri-treatment given to DSS-challenged mice pre-
served their PPs integrity, the number of both subsets of
PPs B cells (Fig. 5a, b), and reduced the B cell
accumulation in MLNs (Additional file 1: Fig. S5D). Fur-
ther, L. reuteri-treatment reduced the ileal infiltration of
IgA+ plasma cells (Additional file 1: Fig. S5E), and re-
stored the DSS-induced shift of SIgA-coated bacteria
(Additional file 1: Fig. S5F). A strong negative correl-
ation between body weight loss and B cell numbers in
PPs following DSS-treatment was detected (Fig. 5d), sup-
porting that the effects by L. reuteri on PPs B cells are
important for preventing colitis. Again, part of the pro-
biotic effect can be explained by the local S1P/S1PR1
Fig. 4 L. reuteri promotes B cell IgA-responses in a Tfh-PD-1-dependent manner. a The area of IgA+ plasma cells (anti-CD138) quantified in ileal
and colonic tissues, n = 5 mice per group (duplicate slides per mouse, scale bars equal 100 μm). b Free IgA (μg/ml, ELISA) in the lumen of ileum
and colon (n = 10–11 mice per group) and c Serum IgA and IgG concentrations (μg/ml, ELISA, n = 5-6 mice per group). d Flow cytometry of
IgA+ bacteria in ileum (n = 16-17 mice per group). e, f Ileal microbiome assessed by 16S rRNA gene amplicon sequencing. Microbial community
diversity was calculated as α-diversity in mice treated with L. reuteri and/or DSS compared to controls, n = 4–9 mice per group. Data are
presented as median values. g Localization of PD-1+ T cells in PPs stained with anti-PD-1 (red), anti-CD3 (green), and Hoechst (blue, scale bar
equals 100 μm) from three independent experiments. h Flow cytometry of Tfh cells and PD-1 expression (n = 13-14 mice per group). A histogram
of PPs and spleen indicating a uniquely high expression of PD-1 in PPs T cells. i Design of PD-1 monoclonal antibodies blocking (blue arrows)
and CD4+ T cell depletion (black arrows) experiments and effects on the number of B cell subsets (n = 6–13 mice per group). j, k Free IgA
production and quantification of IgA+ bacteria in the ileum from PD-1 (mAb) blocking experiments (n = 6 mice per group). Data are presented as
mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 using two-tailed Student’s t test or ANOVA with Tukey’s post hoc test
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signaling in the PPs, as co-treatment with FTY720 to
DSS-treated mice mimicked the effect of probiotics with
maintained pre-GC-like B cells in PPs (Fig. 5b) and de-
layed disease onset (Fig. 5c, Additional file 1: Fig. S5H).
DSS-treatment induced a major shift of the bacterial
community composition into a dysbiotic state (Fig. 5e),
including reduced α-diversity in both ileum and colon
(Fig. 4e, Additional file 1: Fig. S4C). The bacterial taxa
Erysipelotrichaceae in the ileum (Fig. 5f) and Escheri-
chia-Shigella (affiliated with Enterobacteriaceae) in the
colon (Additional file 1: Fig. S5I) were identified as the
main pathobionts, with their relative abundance increas-
ing from less than 2% in healthy animals to up to 80% in
DSS-treated mice, while the relative abundance of S24-7
was decreased by DSS at both sites (Fig. 5g, Additional
file 1: Fig. S5J). L. reuteri-treatment preserved the α-
diversity of colonic microbiota, the ileal Lactobacillaceae
from DSS challenge (Additional file 1: Fig. S4C, Fig. 5h),
and inhibited the overgrowth of Erysipelotrichaceae and
Escherichia-Shigella (Fig. 5f, Additional file 1: Fig. S5I).
It also caused an obvious increase of Bifidobacteriaceae
and Coribacteriacease in the ileum (Fig. 5e) and main-
tained the dominant S24-7 population in the colon
(Additional file 1: Fig. S5J).
Thus, we report that L. reuteri-treatment protects
against intestinal inflammation by maintaining the func-
tions of PPs, which modifies intestinal IgA production and
prevents inflammation-induced microbiota dysbiosis.
Discussion
The strategic location of the PPs facing the ileal lumen
ensures continuous exposure to and sampling of anti-
gens, resulting in intense B cells activation and IgA in-
duction [10, 14, 15]. Here we demonstrate that orally
administered L. reuteri R2LC regulates distinct B cell
subsets in the PPs of mice, which ultimately results in
augmented IgA production, modified microbiota, and
protection against colitis. Thus, the PPs act as relays that
sense, enhance and transmit signals from L. reuteri,
which for the first time explains how gut homeostasis
and the intestinal microbiome can be affected even
though the probiotics represent only a small part of the
microbiota while transiting.
The antibody-mediated immune-selection of gut
microbiota is orchestrated by B cells in PPs that produce
high or low affinity IgA in a T cell-dependent or inde-
pendent manner [26]. To efficiently mount antibody re-
sponses, B cells display high transcriptional, metabolic,
and functional plasticity [20, 22], making the identifica-
tion based on surface markers challenging [27]. The
current study therefore separated B cells in PPs by size,
which resulted in phenotypically, transcriptionally and
spatially distinct B cell subsets: large GC-like B cells
(GL7+/S1PR1−/Ki67+/Bcl6, CD69 expressing) located in
the GC area, and small pre-GC-like B cells (GL7-/
S1PR1+/Bcl6, CCR6 expressing) of the SED in PPs.
Small pre-GC-like B cells are characterized by an
innate-like phenotype not previously demonstrated for B
cells in the PPs. In line with this observation, marginal
zone B cells, IL7RhiCCR6+ lymphocytes, and NK-like B
cells have been detected in spleen and lymph nodes [28–
30], and are characterized by the production of antibac-
terial agents, high capacity for chemotaxis, and lipid
antigen binding. Interestingly, the former two cell types
are activated and mobilized using S1PR1 within lymph-
oid tissues for bacterial antigen sampling [28, 30]. We
found that S1PR1 was exclusively expressed by the pre-
GC-like B cells of the SED and interspersed between
the FAEs, similarly to what was found in a model of oral
immunization as GL7-CCR6+ B cells made close contact
with M cells and antigens [14]. Komban and co-workers
then speculated that these B cells thereafter migrate to
GC using CCR6, thus enabling a strong antigen-specific
IgA response [14]. The model of oral immunization is
different from the probiotic treatment of the current
study, and whether pre-GC-like B cells from the SED
can become GC-like B cells, or if they are committed to
defense, remains to be determined. However, we found
that L. reuteri R2LC favors the retention of S1PR1+ pre-
GC-like B cells in the SED area by increasing local S1P
availability through different means [31]. During inflam-
mation, the importance of S1PR1 in regulating T cells
egress from lymph nodes and consecutive infiltration to
(See figure on previous page.)
Fig. 5 L. reuteri provides protection against DSS-induced colitis, disruption of Peyer’s patches and intestinal dysbiosis. a Macroscopic analysis of
the PPs surface area (mean area of PPs per mouse, mm2, n = 5 mice per group) in WT mice (control), WT mice receiving DSS (DSS, 3% in drinking
water for 7 consecutive days) as well as mice receiving L. reuteri R2LC was given daily to WT mice for 14 days starting 7 days prior to DSS-
treatment (L. reuteri-DSS). Histological analysis of the PPs height (μm, serially sectioned with all slides per PP analyzed, n = 5 mice per group, scale
bars equal 200 μm). b Flow cytometry of live CD3-CD19+B220+ B cells, small-pre-GC-like and large-GC-like B cells in PPs (n = 6–17 mice per
group). c Body weight change and disease activity index of DSS-treated mice and mice co-treated with L. reuteri (n = 9 mice per group) or
FTY720 (n = 6 mice per group). d Pearson correlation of PPs B cell number and body weight loss (%) (n = 24 mice). e Bar graph depicts bacterial
community composition of individual mouse, n = 4 mice per group. f–h Relative abundance of Erysipelotrichaceae, S24-7 and Lactobacillaceae in
the ileal microbiota (n = 4–9 mice per group). Data are presented as median values. Contrast analysis demonstrated that bacterial taxa changed
significantly with DSS-treatment (diseased P < 0.05) and was preserved by L. reuteri-treatment (protected P < 0.05). Data are presented as mean ±
SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 using ANOVA with Tukey’s post hoc test
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the effector sites, has been intensively studied using the
immunosuppressive drug FTY720 (a S1PR1 agonist)
[31–34], believed to exert its effect at least partly by re-
ducing T cell velocity in lymph nodes [35]. Here, we
demonstrate that the probiotic L. reuteri R2LC repro-
duces the anti-inflammatory properties of FTY720 in
DSS-colitis by affecting the population of S1PR+ 1 B cells
in the PPs.
The largest production of IgA occurs in the intestine,
where it coats 40–80% of small intestinal bacteria in hu-
man and mice and is crucial for microbiota homeostasis
[36]. Naturally occurring variations in fecal IgA levels
have been demonstrated, and mice with lower IgA con-
centration are more susceptible to infection and inflam-
mation [9, 11], while mice with higher IgA
concentration were more resistant to colitis [11]. The in-
testinal resident flora undergoes IgA-mediated selection,
where high affinity, T cell-dependent, IgA production
tends to target bacteria with pathogenic potential [26],
even though the underlying mechanisms, which are
probably numerous and not mutually exclusive, are still
not fully understood [26]. In addition to expanding the
population and the innate-like properties of the pre-GC-
like B cells in the PPs, L. reuteri-treatment also ex-
panded the population of large PPs B cells of the GC-
like phenotype. This resulted in the induction of high af-
finity IgA production, as their cell cycle and proliferation
gene programs were down-regulated, while T cell inter-
actions were upregulated through the PD-1 pathway.
These L. reuteri-primed PPs B cells resemble the
Bcl6lowCD69hi post-GC B cells present in lymph nodes,
which are reported to be distinct from the conventional
GC B cells as they feature low proliferative but high
CD40-Tfh-interactive capacity and is destined for IgA
plasma differentiation [21]. L. reuteri also induced in-
creased levels of local IL-21 in the PPs, which was sug-
gested to act in synergy with TGFβ1 [37] and therefore
may promote the PPs GC-like B cell-IgA differentiation
via TGFβ-1 signaling. The observed effects by L. reuteri
on augmented IgA induction and production resulting
in higher titer of free IgA in the ileum and improved
IgA-bacteria binding capacity, are likely to affect the
composition of the gut microbiota. Indeed, the current
study observes changes in the microbiome signature in
the intestine of healthy as well as colitic mice. We there-
fore suggest that the intestinal microenvironment shaped
by L. reuteri-induced IgA favors symbiotic bacteria
growth while resists colonization of pathobionts [2] and
thereby increases the resistance to DSS-induced
dysbiosis.
Interactions between L. reuteri and the intestinal im-
mune cells have previously been shown to influence host
health and disease [7]. However, the relevance of the sci-
entific observations for therapeutic use materializes with
the delineation of the exact mechanism of actions. For
instance, the probiotic L. reuteri strains WU and 100-23
have been demonstrated to drive the differentiation of
ileal CD4+CD8aa+ intraepithelial lymphocytes that are
responsible for oral tolerance [4]. In addition, L. reuteri
DSM 17938 has been reported to shift the Th1/Th17
paradigm in a mouse model of multiple sclerosis [38]. In
immune checkpoint blockade-associated colitis, L. reu-
teri ATCC PTA 6475 was found to ameliorate inflam-
mation by inhibiting Group 3 innate lymphoid cell
activities [3]. These findings underscore the diverse effects
by which probiotic L. reuteri provide health benefit [7].
Here we add to this by demonstrating that L. reuteri-treat-
ment primes the intrinsic functions of PPs B cells in
healthy mice, resulting in increased IgA production and a
microbiota favoring symbiotic bacteria growth while
resisting colonization of pathobionts [2], and increasing
the resistance to DSS-induced dysbiosis. The recent suc-
cesses in the treatment of recurrences of Clostridium diffi-
cile infection by first- and new-in-class investigational
microbiome-based products (RBX2660; NCT03244644
and SER-109; NCT03183128) evaluated for Biologics Li-
cense by the FDA, are milestones to the entire field. The
emerging pipeline of the therapeutic use of live bacterial
products (LBPs) and microbiome therapeutics include sin-
gle strains, consortia, diagnostics as well as genetically
modified single strains, addressing a wide range of unmet
medical needs covering skin, GI tract, lung, women’s
health, oncology, and neurodegenerative disease in both
human and veterinary medicine [39].
Conclusions
In summary, we demonstrate that L. reuteri R2LC regu-
lates the inter-dependent and site-specific B cell re-
sponses in PPs. We found that IgD+/GL7-/S1PR1+/Bcl6,
CCR6 expressing pre-GC-like B cells in the SED interact
with FAE and exhibit innate-like properties, and that L.
reuteri upregulates the bacterial defense gene program
of these cells and expands the population size in a S1P/
S1PR1-dependent manner. In addition, we found that L.
reuteri increases the population size of GL7+/S1PR1-/
Ki67+ B cells, the effector cells in the GC area of PPs,
and reprograms their gene signature to promote metab-
olism and GC functions. Finally, L. reuteri increased
both TGFβ1 and Tfh-PD-1 signaling in GC-like B cells,
and thereby augmented the intestinal B cell-IgA re-
sponses. Together, these results reveal that L. reuteri
R2LC exploits the PPs B cell subsets and primes their in-
trinsic functions, which ultimately results in an
inflammation-resistant microenvironment and a bacter-
ial community resilient to dysbiosis in both the ileum
and colon. The finding that probiotic bacteria such as L.
reuteri utilizes the PPs to transmit and enhance their ef-
fects for the first time explains how these bacteria can
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confer intestinal health effects despite that they do not




Mice used in this study were from a C57Bl/6 back-
ground with wild type or CX3CR1GFP/+ genotype. WT
male mice were purchased from Taconic M&B,
Denmark. Mice were housed under standardized condi-
tions (21–22 °C, 12-h light and 12-h dark cycle) in SPF
facility and were used at 10–12 weeks old under guide-
lines of the Swedish National Board for Laboratory ap-
proved by the Swedish Laboratory Animal Ethical
Committee in Uppsala.
Bacteria preparation and biologics
Limosilactobacillus reuteri subsp. rodentium R2LC (a
kind gift from Siv Ahrné, Lund University, Sweden) [40],
L. reuteri subsp. reuteri ATCC PTA 4659 and L. reuteri
subsp. reuteri ATCC PTA 6475 (kind gifts from BioGaia
AB, Sweden) [41] were grown in MRS broth (Oxoid) at
37 °C for 20 h. Bacteria were harvested at early stationary
phase, washed with PBS, concentrated 100X and stored
at -80 °C in freezing solution (0.82 g K2HPO4, 0.18 g
KH2PO4, 0.59 g sodium citrate, 0.25 g MgSO4 × 7 H2O,
and 172mL glycerol (87%) diluted to 1000mL with
dH2O). 10
8 cfu (resuspended in 100 μl of PBS) were
given perorally (p.o.) for 7 consecutive days. For PD-1
blocking experiments, mice were injected i.p. with
200 μg α-PD-1 (RMP1-14, BioXcell) or equivalent rat
IgG (2A3, BioXcell) every other day during the 7-day
course of L. reuteri-treatment. For CD4+ T cell deple-
tion, 200 μg of rat-anti mouse CD4 mAb (GK1.5, BioX-
cell) were injected i.p. at days 3 and 6, as illustrated (Fig.
4i). DSS-mediated colitis was induced by administration
of 3% (w/v) DSS (M.W. = 40,000 Da; TdB Consultancy
AB) in drinking water for 7 consecutive days. The onset
of colitis and severity was assessed daily based on clinical
measurements including weight loss, stool consistency,
and blood reaction in the feces, calculated as a disease
activity index scoring from 0 to 4 [8]. L. reuteri R2LC
was given daily for 14 days starting 7 days prior to DSS-
treatment (L. reuteri-DSS). In addition, mice were sub-
jected to i.p. injection of a S1PR1 agonist FTY720 (1 mg/
kg body weight) or a vehicle control for 4 consecutive
days during DSS and sacrificed 3 days later.
Plasmid generation and construction of L. reuteri
R2LC_ΔADO
The draft genome of L. reuteri R2LC was used to identify
the gene putatively encoding the 5′-nucleotidase (locus
tag RMX24361) [42]. The upstream (910 base pairs) and
downstream (945 base pairs) regions with oligonucleotide
pairs oVPL3303-oVPL3304 and oVPL3305-oVPL3306
were then amplified by PCR, respectively (Additional file
1: Table S3). With oligonucleotide pair oVPL187-
oVPL188, the backbone of plasmid pVPL3002 (a suicide
vector) was amplified and was integrated in the chromo-
some, which renders cells sensitive to vancomycin [43].
The three PCR amplicons were fused by ligation cycle re-
action [44] with bridging oligonucleotides oVPL3307,
oVPL3308, and oVPL3309, followed by ethanol precipita-
tion of the DNA [45], and was visualized by Pellet Paint
co-precipitant (EMD Millipore). Electrocompetent E. coli
EC101(encodes RepA in trans to support replication of
repA− plasmids) were prepared using standard procedures
[45, 46]. The insertion of the 1.8 kb fragment was con-
firmed by PCR (oligonucleotide pair oVPL49-oVPL97,
which flanks the cloning site in pVPL3002, Additional file
1: Table S3). While the integrity of the cloned DNA se-
quence was confirmed by sequence analysis with the
Sanger method.
Next, we generated an in-frame deletion of L. reuteri
RMX24361 according to a previously established protocol
[43] and constructed L. reuteri R2LC_ΔADO. Briefly, we
electroporated 5 μg of the pVPL3002-derivative containing
the deletion cassette into L. reuteri R2LC. Following recov-
ery, cells were plated on MRS agar containing 5 μg/ml
erythromycin. Colonies were screened by PCR using oligo-
nucleotide combination oVPL3310-oVPL3311-oVPL97 and
oVPL3310-oVPL3311-oVPL49 to identify homologous re-
combination upstream or downstream, respectively, of the
target gene (Additional file 1: Table S3). A single-crossover
mutant was cultured for 10 generations and recovered on
MRS plates containing 400 μg/ml vancomycin. Colonies re-
sistant to vancomycin have lost the suicide vector following
a second homologous recombination event to yield either a
wild-type or recombinant genotype. Finally, the deletion
genotype was confirmed by PCR with oligonucleotide
oVPL3310-oVPL3311 and by sequence analysis with the
Sanger method.
Histology
The terminal Peyer’s patches, distal ileum, and colon tis-
sues were fixed in 4% paraformaldehyde (PFA) over-
night, dehydrated in 70% ethanol, and embedded in
paraffin. Four μm thick sections were stained with
hematoxylin and eosin (H&E). The whole terminal PP
was serially sectioned. All slides of one PP were evalu-
ated, and the arch of PP’s dome was identified, thus the
height was measured. Ileal tissue sections were scored
(blindly) by assessing mucosal architecture (villus blunt,
distortion, and atrophy), epithelial changes (erosion and
ulceration), and inflammatory immune cell infiltration
based on a 0-12 scoring system (Additional file 1: Table
S4). Duplicate was used for all tissue sections and was
imaged with a light microscope (Leica DFC 420C).
Liu et al. Microbiome           (2021) 9:198 Page 13 of 18
Immunofluorescent microscopy
Peyer’s patches, distal ileal and distal colon tissue sam-
ples were fixed in 4% PFA overnight, dehydrated in 30%
of sucrose, embedded in O.C.T. (Tissue-Tek), and sec-
tioned (10 μm). Sections were fixed in either 4% PFA or
acetone shortly for 2 minutes and permeabilized (0.5%
Triton™ X-100, Sigma-Aldrich) before antibody incuba-
tion. Antibodies raised against the following mouse anti-
gens were used: B220 (AF647, cloneRA3-6B2,
BioLegend), CD3 (AF488, clone17A2, BioLegend),
CD21/CD35 (AF594, clone7E9, BioLegend), CD138 (un-
conjugated, clone281-2, BioLegend), CD279/PD-1
(AF647, clone29F.1A12, BioLegend), GL7 (FITC, clo-
neGL7, BD Bioscience), IgA (FITC, cloneC10-3, BD Bio-
science), IgD (Pacific blue, 11-26c2a, BioLegend), Ki67
(unconjugated, cloneMIB-1, Abcam), DEFa3 (unconju-
gated, RBM6, antibodies-online), pimonidazole (Pacific
Blue, Hypoxyprobe), and Phalloidin (AF555). Detection
of CD138, Ki67, and DEFa3 required secondary anti-
bodies to amplify signals with goat anti-rat-IgG-AF555
and chicken anti-rabbit-IgG-AF488 (Thermo Fisher Sci-
entific), respectively. Nucleus was stained with Hoechst
33342 (Thermo Fisher Scientific) and mounted using
Fluoromount-G® (SouthernBiotech). For whole mount
staining, PPs from CX3CR1GFP/+ mice were stained with
intravenous CD31 (AF555 conjugated, clone309,
eBioscience) prior to sampling, then PPs tissue was re-
moved and fixed using BD Cytofix/Cytoperm solution
for 1 hr and permeabilized with BD Perm/Wash buffer
for 5 min before antibody incubation. The whole PPs
were stained with wheat germ agglutinin (CF®405M,
Biotium) and placed in a 30% solution of glycerol in PBS
on the slide. All samples were imaged with a Zeiss con-
focal Laser Scanning Microscope 780.
Flow cytometry and cell sorting
All visible PPs were harvested and pooled when prepar-
ing single cell suspensions for flow cytometry. Single-cell
suspensions from PPs, MLNs, and spleen were prepared
by mashing organs through 40 μm cell strainers in PBS
containing 0.05% FBS and 2mM EDTA (MLNs or
spleen cells were used as staining control). PPs cells
were stained with anti-CD3 biotinylated antibody (17A2,
BioLegend) and were subjected to Magnetic Cell Sorting
system (Miltenyi Biotec) to separate CD3+ and CD3-
fractions. Samples were blocked with anti-CD16/32
(2.4G2, BD Bioscience), stained with antibodies anti-
B220 (RA3-6B2), CD19 (6D5), CD3 (17A2), CD4
(GK1.5), CD279 (29F.1A12), NK1.1 (PKB6) from BioLe-
gend; CXCR5 (2G8), GL7 (GL7); S1P1/EDG-1 (T4-H28)
from R&D; CD8α (5H10), TCRαβ (H57-597) from
Thermo Fisher Scientific; and CD11c (N418), CD62L
(MEL-14) from eBioscience. Dead cells were excluded
from analysis using the Live/Dead Aqua Viability Kit
(Thermo Fisher Scientific) or 7AAD (BD Bioscience).
For intracellular staining of HIF-1α (351-400/826, Bioss),
TGFβ1 (860206, R&D), IL-21 (149204, R&D), and
DEFa3 (RBM6, antibodies-online), cells were fixed and
permeabilized using either Foxp3/Transcription Factor
Staining Buffer Set (eBioscience) or Fixation/
Permeabilization Solution Kit (BD Cytofix/Cytoperm)
according to the manufacturer’s instructions (BD
Bioscience).
For B cell sorting, single cell suspension of PPs was
prepared and was enriched by negative selection using
MACS columns with a Cocktail of biotin-conjugated
monoclonal antibodies following the manufacturer’s in-
structions (Miltenyi Biotech). The live lineage negative
cells (Lin-, i.e. CD3ε-, CD4-, CD8a-, CD49b-, Gr-1- and
Ter119-) were stained with anti-CD19 and anti-B220
antibodies and sorted by FSC-A as small B and large B
with FACS-AriaIII (BD Bioscience).
In vivo proliferation assay
Mice were injected i. p. with 500 μg of the nucleoside
analog EdU (Baseclick GmbH) in PBS twice, i.e., 24 h
and 3 h before euthanizing. After, PPs were prepared for
single cell suspension and stained for surface antigens as
described, followed by EdU detection using the EdU FC
Kit 647 (Baseclick GmbH) according to the manufac-
turer’s protocol, with anti-Ki67(SolA15, eBioscience)
staining afterwards.
RNA extraction and microarray analysis
Total RNA of sorted small B and large B cells (live
Lin−CD19+B220+) and PPs tissue were extracted with
RNeasy Plus Micro Kit (QIAGEN). Total RNA of sorted
B cells was submitted to Array and Analysis Facility, De-
partment of Medical Science, Uppsala University. RNA
integrity was evaluated by Agilent 2100 Bioanalyzer sys-
tem (Agilent Technologies). Biotinylated sense-strand
cDNA from the entire expressed genome was generated
according to the GeneChip™ WT Pico Reagent Kit Man-
ual (P/N 703262, ThermoFisher Scientific). Clariom™ D
mouse arrays (previous name: GeneChip™ Mouse Tran-
scriptome Array 1.0) were hybridized for 16 hours in a
45 °C incubator, rotated at 60 rpm. According to the
GeneChip™ Expression Wash, Stain and Scan Manual
(P/N 702731, Thermo Fisher Scientific) the arrays were
then washed and stained using the GeneChip™ Fluidics
Station 450 and finally scanned using the GeneChip™
Scanner 3000 7G.
The raw data were normalized to gene level in Expres-
sion Console (Affymetrix) using the SST-RMA version
of the robust multi-array average method. Subsequent
analysis of the gene expression data (log2 expression of
genes ranging between 0 and 20) was carried out in the
statistical computing language R. In order to search for
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the differentially expressed genes between groups, an
empirical Bayes moderated t-test was applied using the
‘limma’ package (version 3.26.1), p-values were adjusted
with false discovery rate control (FDR) using the method
of Benjamini and Hochberg. Genes differentially
expressed were further selected and put into The Data-
base for Annotation, Visualization and Integrated Dis-
covery (DAVID) v6.8 for gene enrichment ontology
analysis related to Biological Process (BP). That is, ex-
pression values under 5 were considered background.
For large B cells and small B cells comparison, genes
whose fold-change over 1 and FDR q < 0.05 (total 383
gene transcripts). For L. reuteri-treated large B and con-
trol large B, FDR q < 0.05 (total 285 gene transcripts)
and for L. reuteri-treated small B and control small B,
FC over 1 and FDR q < 0.1 (26 gene transcripts).
Quantitative real-time PCR
Total RNA was transcribed with a High-Capacity cDNA
kit (Thermo Fisher Scientific). Quantitative RT-PCR was
performed using Fast SYBR™ Green Master Mix on a
QuantStudio™5 Real-Time PCR System, in a 384-well
format (Thermo Fisher Scientific). The geometric mean
of 3 reference genes GAPDH, TBP, and 36B4 was used
for normalization. Relative expression of target genes
was determined. The specific primers are listed in Add-
itional file 1: Table S3.
Analysis of IgA-bound bacteria and free IgA
IgA binding bacteria were analyzed by flow cytometry as
previously described [47, 48]. In brief, luminal content
from the ileum and colon were collected, suspended in
filtered PBS (100 μl to 10 mg feces), homogenized, and
centrifuged at 400g for 5 min to remove large debris.
Supernatant-containing bacteria were filtered through a
sterile 70 μm strainer and centrifuged at 8000g for 10
min to separate free immunoglobulins. The supernatant
was further centrifuged at 19,000g for 10 min and col-
lected for free IgA assay using IgA ELISA quantitation
Set (Bethyl). The pellet was resuspended in 1 ml of BSA-
PBS (1% w/v) and blocked on ice for 15 min. After being
stained with anti-mouse IgA (FITC, C10-3, BD Bio-
science) for 30 min on ice, samples were washed with fil-
tered PBS, resuspended in 4 μg/ml propidium iodide
(PI)/PBS, and analyzed by LSR Fortessa (BD Bioscience).
Multi-plex mesoscale assay and ELISA
IL-10, IFN-γ, TNF-α, IL1-β, IL-6, CXCL1, IL-2, IL-4, IL-
5, and IL-12 were measured in PPs, distal colon using
Multi-Plex Mesoscale assay following manufacturer’s in-
structions (MesoScale Discovery). Tissues were homoge-
nized and measured for protein concentration by the
BCA method and values were normalized to tissue pro-
tein content. TGFβ1 was analyzed by ELISA (Mouse
TGF-beta 1 DuoSet, R&D System), serum IgG and IgA
concentrations were determined by ELISA quantitation
Set (Bethyl).
DNA extraction and microbiota analysis
DNA was extracted from 180 to 220mg of intestinal
lumen content using QIAamp Fast DNA Stool Mini kit
(Qiagen). The Illumina MiSeq Dual Index Amplicon Se-
quencing was performed. Briefly, the bacterial V3-V4 16S
rRNA gene regions were PCR amplified from each sample
using a composite forward primer and a reverse primer
containing a unique 8-base index primer, designed to tag
PCR product from respective samples. The forward pri-
mer was Illumina adapter-N4-341F: 3′-ACACTCTTTC
CCTACACGACGCTCTTCCGATCTNNNNCCTACGG
GNGGCWGCAG-5′. The reverse primer was Illumina
adapter-805R:3′-AGACGTGTGCTCTTCCGATCTGAC
TACHVGGGTATCTAATCC-5′. PCR reactions con-
sisted of master mix (0.5 μl of each primer, 4 μl of Q5 re-
action buffer, 0.2 μl (0.02 U/μl) Q5 HF DNA polymerase
(New England Biolabs), 2 μl of dNTPs, 11.8 μl of Milli-Q
water) and 1 μl of DNA template. Reaction conditions
were 1min at 98 °C, followed by 20 cycles of 10 s at 98 °C,
30 s at 58 °C and 30 s at 72 °C, and a final extension step
at 72 °C for 2min on a Bio-Rad thermocycler. Duplicates
were run in 20 μl reactions for each sample, combined,
purified with Agencourt Ampure magnetic purification
beads (Beckman Coulter). Products were visualized by gel
electrophoresis. Then, a second PCR was conducted using
1:10 dilutions of the first PCR product for attaching stand-
ard Illumina handles and index primers. The steps were
the same as mentioned above, except that it was 18 ther-
mal cycles and the annealing temperature was 63 °C. PCR
products were quantified with Picogreen dsDNA assay ac-
cording to the manufacturer’s instruction (Thermo Fisher
Scientific) to facilitate pooling equimolar amounts of
amplicon for sequencing. Finally, a master DNA pool was
generated and sequenced on an Illumina HiSeq 2500 se-
quencer at the SciLifeLab SNP/SEQ sequencing facility
(Uppsala, Sweden).
The Illumina sequencing data output was processed
according to the cut-offs and pipeline developed by Sin-
clair et al. [49]. Sequences were assigned to operational
taxonomic units (OTUs) by using a closed reference-
based OTU picking method in QIIME v1.8. For every
OTU, the sequence was checked as a query against the
SILVAMOD database using the CREST software version
2.0. For comparative measurements of total bacterial
load, a primer for total 16S rRNA primers was used. The
data were normalized by sample weight.
Statistical analysis
Statistical analysis was performed using Graphpad Prism
software v.6.0. Two-tailed Student’s t test was used for
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direct comparison of two groups, and one-way analysis
of variance (ANOVA) with Tukey’s post hoc test to
compare all groups. Difference of DAI was calculated
and compared as area under the curve. For microbial
community composition analysis, bioinformatics was
performed using the cumulative-sum scaling method
[50]. VEGAN package version 2.0-7 and the R statistical
framework version 2.11 were used to perform multivari-
ate analysis of microbiota, α-diversity is represented by
Shannon index and ANOVA analysis with Contrast.
Data were presented as mean ± SEM., p < 0.05 was con-
sidered significant.
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